Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group
Клиническое ведение и диагностика заболевания CLN2: консенсус группы бразильских экспертов
2023-03-01
SCID: 54.1/38gtsvnr
Discuss with AI
CLN2 diseasecerliponase alfaenzyme replacement therapymolecular and biochemical testingneuronal ceroid lipofuscinosis type 2
Figures from the paper
Abstract (AI)
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare neurodegenerative genetic disease that affects children in early life. Its classic form is rapidly progressive, leading to death within the first 10 years. The urge for earlier diagnosis increases with the availability of enzyme replacement therapy. A panel of nine Brazilian child neurologists combined their expertise in CLN2 with evidence from the medical literature to establish a consensus to manage this disease in Brazil. They voted 92 questions including diagnosis, clinical manifestations, and treatment of the disease, considering the access to healthcare in this country. Clinicians should suspect CLN2 disease in any child, from 2 to 4 years old, with language delay and epilepsy. Even though the classic form is the most prevalent, atypical cases with different phenotypes can be found. Electroencephalogram, magnetic resonance imaging, molecular and biochemical testing are the main tools to investigate and confirm the diagnosis. However, we have limited access to molecular testing in Brazil, and rely on the support from the pharmaceutical industry. The management of CLN2 should involve a multidisciplinary team and focus on the quality of life of patients and on family support. Enzyme replacement therapy with Cerliponase α is an innovative treatment approved in Brazil since 2018; it delays functional decline and provides quality of life. Given the difficulties for the diagnosis and treatment of rare diseases in our public health system, the early diagnosis of CLN2 needs improvement as enzyme replacement therapy is available and modifies the prognosis of patients.
Key Findings
1
Brazil has limited access to molecular testing, with diagnostic support often relying on the pharmaceutical industry.
2
CLN2 disease should be suspected in children aged 2–4 years presenting with language delay and epilepsy, including atypical phenotypes.
3
CLN2 management should use a multidisciplinary approach focused on patient quality of life and family support.
4
Cerliponase alfa enzyme replacement therapy, approved in Brazil since 2018, delays functional decline and improves quality of life, highlighting the need for earlier diagnosis.
5
Electroencephalography, magnetic resonance imaging, and molecular and biochemical testing are the principal tools for investigating and confirming CLN2 disease.
Research Object
CLN2 disease (neuronal ceroid lipofuscinosis type 2) in children in Brazil
Research Subject
Clinical diagnosis and management of CLN2 disease, including early detection, diagnostic confirmation, multidisciplinary care, enzyme replacement therapy, and quality-of-life outcomes
Publication Details
Publication Date
2023-03-01
Journal
Publisher
ISSN
Cited by
16
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest